Liftstream is an executive search recruitment company in the life sciences sector
Executive and Board Director Appointments in Oncology and Rare Diseases
Third Rock Ventures portfolio company, Voyager Therapeutics, a gene therapy player in the field of CNS based out of Cambridge, Mass. have appointed Michael Higgins to the Board of Directors. Mr. Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation, with which Voyager Therapeutics now has a partnership, from 1997 through 2003 in a variety of leadership roles, including vice president of corporate finance and vice president of business development. While at Genzyme, he was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases.
Executive Recruitment Round-up October 2014
Authored by James Sheppard
Soaring biotech equity heightens recruitment challenges
Authored by Karl Simpson
Gilead Expands Oncology Offering with Purchase of YM Bioscience
In mid-December Gilead Sciences announced they had signed a deal to purchase the Canadian company YM Bioscience for $510m in cash ($2.95 per share). The purchase gives Gilead access to a second experimental drug to treat a rare blood and immune cell disorder.
Pharma’s emerging markets push creates talent gap
Liftstream looks at how the emerging markets is placing demands on talent and creating gaps in expertise within key functions like regulatory affairs.